Stephanie Giesler
Psychiatric/Mental Health · Waterloo, IANPI 1750845954
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 615 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 615 payments — averaging $8.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$932
- Neurocrine Biosciences, Inc.$884
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$874
- Alkermes, Inc.$797
- Johnson & Johnson$444
- Otsuka America Pharmaceutical, Inc.$426
- plus $944 from 14 others
What the payments were for
- Food & beverage$5,13197%
- Education$1713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 144 | $932 |
| Neurocrine Biosciences, Inc. | 172 | $884 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 72 | $874 |
| Alkermes, Inc. | 51 | $797 |
| Johnson & Johnson | 75 | $444 |
| Otsuka America Pharmaceutical, Inc. | 42 | $426 |
| Teva Pharmaceuticals USA, Inc. | 11 | $214 |
| Corium, LLC | 18 | $161 |
| Indivior Inc. | 6 | $122 |
| Lundbeck LLC | 4 | $81 |
| Supernus Pharmaceuticals, Inc. | 4 | $79 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Ironshore Pharmaceuticals Inc. | 3 | $44 |
| Merck | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Itamar Medical Inc | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$111
How this compares
$5,301 in reported general payments places this provider in the 90th percentile of 443 psychiatric/mental health providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 194 | $289,636 |
| Invega SustennaPaliperidone Palmitate | 35 | $115,157 |
| RexultiBrexpiprazole | 40 | $50,149 |
| FetzimaLevomilnacipran Hcl | 48 | $23,864 |
| CaplytaLumateperone Tosylate | 12 | $20,254 |
| TrintellixVortioxetine Hydrobromide | 69 | $17,644 |
| QuviviqDaridorexant Hcl | 34 | $16,635 |
| VyvanseLisdexamfetamine Dimesylate | 29 | $10,296 |
| DayvigoLemborexant | 11 | $3,817 |
| Quetiapine Fumarate | 222 | $3,230 |
| Clonazepam | 305 | $3,133 |
| Adderall XrDextroamphetamine/Amphetamine | 19 | $3,066 |
| Paliperidone ErPaliperidone | 22 | $2,490 |
| Doxepin Hcl | 44 | $2,343 |
| Trazodone Hcl | 157 | $2,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $932 | $313,500242 claims |
| Johnson & JohnsonInvega Sustenna | $444 | $115,15735 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $426 | $50,14940 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $15 | $27,94098 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $874 | $20,25412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Waterloo
- Kama AusbornWaterloo$64K
- Abby KolthoffWaterloo$7K
- Evans KomenWaterloo$7K
- Emily SwartleyWaterloo$4K
- Tarrah HollidayAtlantic$421K
- Kelsie SwisherParkersburg$235K
- Jennifer BradleyCedar Rapids$66K
- Quentin ChambersDes Moines$40K
- Tenaea JeppesonFort Dodge$38K
- Jennifer WittmanCoralville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.